Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Vision HexaCard

Genomic Vision has launched HexaCard, a new service for the control and optimization of genome editing. Primarily for gene therapy and biomanufacturing, HexaCard addresses challenges of cellular cross-contamination, misidentified cell lines, and the use of cell cultures at high passage. Based on Genomic Visions' proprietary Molecular Combing Technology, it integrates copy number determination, orientation assessment, integration site identification, genetic integrity of the target region, on- and off-target insertions, and a genetic signature for stability assessment into a single assay.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.